Key clinical point: Maintenance therapy with either bevacizumab or pemetrexed is efficacious against advanced non–small cell lung cancer.
Major finding: There was no difference in overall survival between single-agent bevacizumab, pemetrexed, or the two combined, though the combination was associated with higher toxicity.
Study details: A randomized trial with 1,516 patients treated with induction and 874 treated with maintenance therapy.
Disclosures: The study was supported by grants from the National Cancer Institute. Dr. Ramalingam reported a consulting/advisory role for bevacizumab maker Genentech/Roche and others. Multiple coauthors reported similar disclosures.
Ramalingam SS et al. J Clin Oncol. 2019 Jul 30. doi: 10.1200/JCO.19.01006.